Cargando…

Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis

OBJECTIVE: To conduct a meta-analysis assessing the efficacy and safety of cyclosporine-based combinations for primary immune thrombocytopenia (ITP). METHODS: Randomized controlled clinical trials were collected by systematically searching databases (PubMed®, MEDLINE®, EMBASE, The Cochrane Library,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaojing, Zhu, Wenwei, Bao, Jizhang, Li, Jiekai, Zhou, Yongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869211/
https://www.ncbi.nlm.nih.gov/pubmed/36650914
http://dx.doi.org/10.1177/03000605221149870
_version_ 1784876720327753728
author Li, Xiaojing
Zhu, Wenwei
Bao, Jizhang
Li, Jiekai
Zhou, Yongming
author_facet Li, Xiaojing
Zhu, Wenwei
Bao, Jizhang
Li, Jiekai
Zhou, Yongming
author_sort Li, Xiaojing
collection PubMed
description OBJECTIVE: To conduct a meta-analysis assessing the efficacy and safety of cyclosporine-based combinations for primary immune thrombocytopenia (ITP). METHODS: Randomized controlled clinical trials were collected by systematically searching databases (PubMed®, MEDLINE®, EMBASE, The Cochrane Library, China National Knowledge Infrastructure) from inception to June 2022. All studies included patients with ITP who received cyclosporine-based regimens. We performed comprehensive analyses of the overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, relapse rate, platelet count, and adverse drug reaction (ADR) rate. RESULTS: Seven studies (n = 418) were ultimately included. According to a fixed-effects model, cyclosporine-based combinations improved the ORR and CR rate and reduced the relapse rate. The ADR rate was not increased in the cyclosporine-based combination group. Cyclosporine-based regimens effectively increased the platelet count. Subgroup analysis illustrated that cyclosporine-based combinations were linked to higher ORRs in both children (odds ratio [OR] = 5.74, 95% confidence interval [CI] = 1.79–18.41) and adults (OR = 5.46, 95% CI = 2.48–12.02) and a higher CR rate in adults (OR = 2.97, 95% CI = 1.56–5.63). CONCLUSION: Cyclosporine exhibited efficacy in the treatment of ITP without increasing the risk of ADRs.
format Online
Article
Text
id pubmed-9869211
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-98692112023-01-24 Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis Li, Xiaojing Zhu, Wenwei Bao, Jizhang Li, Jiekai Zhou, Yongming J Int Med Res Meta Analysis OBJECTIVE: To conduct a meta-analysis assessing the efficacy and safety of cyclosporine-based combinations for primary immune thrombocytopenia (ITP). METHODS: Randomized controlled clinical trials were collected by systematically searching databases (PubMed®, MEDLINE®, EMBASE, The Cochrane Library, China National Knowledge Infrastructure) from inception to June 2022. All studies included patients with ITP who received cyclosporine-based regimens. We performed comprehensive analyses of the overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, relapse rate, platelet count, and adverse drug reaction (ADR) rate. RESULTS: Seven studies (n = 418) were ultimately included. According to a fixed-effects model, cyclosporine-based combinations improved the ORR and CR rate and reduced the relapse rate. The ADR rate was not increased in the cyclosporine-based combination group. Cyclosporine-based regimens effectively increased the platelet count. Subgroup analysis illustrated that cyclosporine-based combinations were linked to higher ORRs in both children (odds ratio [OR] = 5.74, 95% confidence interval [CI] = 1.79–18.41) and adults (OR = 5.46, 95% CI = 2.48–12.02) and a higher CR rate in adults (OR = 2.97, 95% CI = 1.56–5.63). CONCLUSION: Cyclosporine exhibited efficacy in the treatment of ITP without increasing the risk of ADRs. SAGE Publications 2023-01-17 /pmc/articles/PMC9869211/ /pubmed/36650914 http://dx.doi.org/10.1177/03000605221149870 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Meta Analysis
Li, Xiaojing
Zhu, Wenwei
Bao, Jizhang
Li, Jiekai
Zhou, Yongming
Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
title Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
title_full Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
title_fullStr Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
title_short Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
title_sort efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
topic Meta Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869211/
https://www.ncbi.nlm.nih.gov/pubmed/36650914
http://dx.doi.org/10.1177/03000605221149870
work_keys_str_mv AT lixiaojing efficacyandsafetyofcyclosporinebasedregimensforprimaryimmunethrombocytopeniaasystematicreviewandmetaanalysis
AT zhuwenwei efficacyandsafetyofcyclosporinebasedregimensforprimaryimmunethrombocytopeniaasystematicreviewandmetaanalysis
AT baojizhang efficacyandsafetyofcyclosporinebasedregimensforprimaryimmunethrombocytopeniaasystematicreviewandmetaanalysis
AT lijiekai efficacyandsafetyofcyclosporinebasedregimensforprimaryimmunethrombocytopeniaasystematicreviewandmetaanalysis
AT zhouyongming efficacyandsafetyofcyclosporinebasedregimensforprimaryimmunethrombocytopeniaasystematicreviewandmetaanalysis